In vitro and preclinical systematic dose-effect studies of Auger electron- and beta particle-emitting radionuclides and external beam radiation for cancer treatment
Ines M Costa,George Firth,Jana Kim,Arshiya Banu,Truc T. Pham,Kavitha Sunassee,Sophie Langdon,Vittorio De Santis,Laurence Vass,Giuseppe Schettino,Gilbert O Fruhwirth,Samantha Y.A. Terry
DOI: https://doi.org/10.1016/j.ijrobp.2024.05.017
IF: 8.013
2024-05-27
International Journal of Radiation Oncology*Biology*Physics
Abstract:Purpose Despite a rise in clinical use of radiopharmaceutical therapies, the biological effects of radionuclides and their relationship with absorbed radiation dose are poorly understood. Here, we set out to define this relationship for Auger electron-emitters [ 99m Tc]TcO 4 and [ 123 I]I, and β − -particle-emitter [ 188 Re]ReO 4 . Studies were carried out using genetically-modified cells that permitted direct radionuclide comparisons. Methods and Materials Triple-negative MDA-MB-231 breast cancer cells, expressing the human sodium/iodide symporter (hNIS) and green fluorescent protein (GFP; MDA-MB-231.hNIS-GFP) were used. In vitro radiotoxicity of [ 99m Tc]TcO 4 , [ 123 I]I and [ 188 Re]ReO 4 was determined using clonogenic assays. Radionuclide uptake, efflux, and subcellular location were used to calculate nuclear-absorbed doses using the Medical Internal Radiation Dose formalism. In vivo studies were performed using female NSG mice bearing orthotopic MDA-MB-231.hNIS-GFP tumors and compared to X-ray-treated (12.6-15 Gy) and untreated cohorts. Absorbed dose per unit activity in tumors and NIS-expressing organs were extrapolated to reference human adult models using OLINDA/EXM®. Results [ 99m Tc]TcO 4 − and [ 123 I]I reduced the survival fraction only in hNIS-expressing cells, whereas [ 188 Re]ReO 4 reduced survival fraction in hNIS-expressing and parental cells. [ 123 I]I required 2.4-fold and 1.5-fold lower decays/cell to achieve 37% survival compared to [ 99m Tc]TcO 4 − and [ 188 Re]ReO 4 , respectively, following 72 hours incubation. Additionally, [ 99m Tc]TcO 4 − , [ 123 I]I and [ 188 Re]ReO 4 had superior cell killing effectiveness in vitro compared to X-rays. In vivo , X-ray led to a greater median survival compared to [ 188 Re]ReO 4 and [ 123 I]I (54 days versus 45 and 43 days, respectively). Unlike the X-ray cohort, no metastases were visualized in the radionuclide-treated cohorts. Extrapolated human absorbed doses of [ 188 Re]ReO 4 to a 1 g tumor were 13.8-fold and 11.2-fold greater than for [ 123 I]I in female and male models, respectively. Conclusions This work reports reference dose-effect data using cell and tumor models for [ 99m Tc]TcO 4 , [ 123 I]I, and [ 188 Re]ReO 4 , for the first time. We further demonstrate the tumor controlling effects of [ 123 I]I, and [ 188 Re]ReO 4 in comparison to EBRT.
oncology,radiology, nuclear medicine & medical imaging